Fangming Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Fangming Guo has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Jie Wang
Cardiac Intensive Care Unit, Yantaishan Hospital, Affiliated to Binzhou Medical University, Yantai City, China
2 shared publicationsWeiping Wan
Department of Ultrasound, Yantaishan Hospital, Affiliated to Binzhou Medical University, Yantai City, China
2 shared publicationsWenbo Liu
Department of Cardiology, Yantaishan Hospital, Affiliated to Binzhou Medical University, Yantai City, China
2 shared publicationsXiaohuan Wang
Department of Cardiology, Gansu Provincial Hospital, Lanzhou, China
2 shared publicationsYanfang Cui
Department of Ultrasound, Yantaishan Hospital, Affiliated to Binzhou Medical University, Yantai City, China
2 shared publicationsYuanying Guo
School of Public Health, LKS Faculty of Medicine, The University of Hongkang, China
2 shared publications
Latest Publications
- Open Access
- 17 April 2026
- Published by Springer Nature in BioMedical Engineering OnLine
- Vol. 25 (1)
Application of multimodal nanotechnology and standardized nursing management in ventricular arrhythmia
Ventricular arrhythmias, particularly ventricular fibrillation, remain a leading cause of sudden cardiac death and pose persistent clinical challenges due to limitations in targeted therapy and the complexity of arrhythmogenic substrates. multimodal nanotechnology has emerged as a promising platform enabling integrated diagnostic and therapeutic functions; however, direct evidence for its application in cardiology remains limited compared to oncology, and significant translational barriers persist. Concurrently, comprehensive nursing and standardized management are critical for optimizing patient outcomes through continuous monitoring, timely intervention, and holistic care. This review critically synthesizes current evidence on multimodal nanotechnology applications in ventricular arrhythmia management, distinguishing between established cardiovascular findings and conceptual extrapolations from other fields. It analyzes technological advantages alongside cardiac-specific limitations—including myocardial targeting challenges, pro-arrhythmic risks, and regulatory complexity. Furthermore, it examines how nanotechnology-based therapies will impact nursing workflows, monitoring protocols, and competency requirements, proposing a framework for integrating these innovations with standardized nursing management. By bridging cutting-edge technological advances with clinical nursing strategies, this article provides a theoretical foundation and practical guidance for fostering multidisciplinary collaboration and advancing comprehensive, patient-centered treatment paradigms for ventricular arrhythmias.
- 17 April 2026
- Published by Springer Nature in BioMedical Engineering OnLine
- Vol. 25 (1)
Open AccessApplication of multimodal nanotechnology and standardized nursing management in ventricular arrhythmia
Ventricular arrhythmias, particularly ventricular fibrillation, remain a leading cause of sudden cardiac death and pose persistent clinical challenges due to limitations in targeted therapy and the complexity of arrhythmogenic substrates. multimodal nanotechnology has emerged as a promising platform enabling integrated diagnostic and therapeutic functions; however, direct evidence for its application in cardiology remains limited compared to oncology, and significant translational barriers persist. Concurrently, comprehensive nursing and standardized management are critical for optimizing patient outcomes through continuous monitoring, timely intervention, and holistic care. This review critically synthesizes current evidence on multimodal nanotechnology applications in ventricular arrhythmia management, distinguishing between established cardiovascular findings and conceptual extrapolations from other fields. It analyzes technological advantages alongside cardiac-specific limitations—including myocardial targeting challenges, pro-arrhythmic risks, and regulatory complexity. Furthermore, it examines how nanotechnology-based therapies will impact nursing workflows, monitoring protocols, and competency requirements, proposing a framework for integrating these innovations with standardized nursing management. By bridging cutting-edge technological advances with clinical nursing strategies, this article provides a theoretical foundation and practical guidance for fostering multidisciplinary collaboration and advancing comprehensive, patient-centered treatment paradigms for ventricular arrhythmias.
- Open Access
- 1 January 2022
- Published by SAGE Publications in Human & Experimental Toxicology
- Vol. 41
Shenfu Administration Improves Cardiac Fibrosis in Rats With Myocardial Ischemia-Reperfusion Through Adenosine A2a Receptor Activation
Objective: Shenfu injection (SFI) is commonly used for cardiac dysfunction in China. Adenosine receptors have been reported to exert anti-fibrosis effects. The intent of this study was to evaluate that SFI attenuates cardiac fibrosis through activating of adenosine A2a receptor (A2aR) in rats with myocardial ischemia-reperfusion (MI/R). Methods: Sprague Dawley male rats were randomly divided into five groups, nine rats in each group. Injections in all rat groups were carried out prior to reperfusion, and in the sham and MI/R groups, only vehicle was injected. Injections in the remaining group were as follows: 5 mL/kg in the SFI group; 15 mg/kg nicorandil in the A2R agonist group; and 5 mL/kg SFI plus 5 mg/kg MSX-3 in the SFI + A2aR antagonist group. Changes in cyclic adenosine monophosphate (cAMP) and the development of myocardial infarction and cardiac fibrosis were documented among the groups. Additionally, the levels of A2aR, collagen Ⅰ, collagen Ⅲ, fibronectin, and matrix metalloproteinase-9 (MMP-9) were measured. Results: Following injection with SFI or nicorandil, the cAMP concentration, infarct area, and cardiac fibrosis induced by MI/R injury were significantly decreased ( p < 0.05). Additionally, the levels of collagen Ⅰ, collagen Ⅲ, fibronectin, and MMP-9 were clearly suppressed by SFI or nicorandil when compared with the MI/R group ( p2aR and collagen I and collagen III was found ( p = 0.00). Conclusion: SFI activated the A2aR to reduce myocardial fibrosis caused by MI/R injury, which provided an underlying mechanism of action of SFI.
- 1 January 2022
- Published by SAGE Publications in Human & Experimental Toxicology
- Vol. 41
Open AccessShenfu Administration Improves Cardiac Fibrosis in Rats With Myocardial Ischemia-Reperfusion Through Adenosine A2a Receptor Activation
Objective: Shenfu injection (SFI) is commonly used for cardiac dysfunction in China. Adenosine receptors have been reported to exert anti-fibrosis effects. The intent of this study was to evaluate that SFI attenuates cardiac fibrosis through activating of adenosine A2a receptor (A2aR) in rats with myocardial ischemia-reperfusion (MI/R). Methods: Sprague Dawley male rats were randomly divided into five groups, nine rats in each group. Injections in all rat groups were carried out prior to reperfusion, and in the sham and MI/R groups, only vehicle was injected. Injections in the remaining group were as follows: 5 mL/kg in the SFI group; 15 mg/kg nicorandil in the A2R agonist group; and 5 mL/kg SFI plus 5 mg/kg MSX-3 in the SFI + A2aR antagonist group. Changes in cyclic adenosine monophosphate (cAMP) and the development of myocardial infarction and cardiac fibrosis were documented among the groups. Additionally, the levels of A2aR, collagen Ⅰ, collagen Ⅲ, fibronectin, and matrix metalloproteinase-9 (MMP-9) were measured. Results: Following injection with SFI or nicorandil, the cAMP concentration, infarct area, and cardiac fibrosis induced by MI/R injury were significantly decreased ( p < 0.05). Additionally, the levels of collagen Ⅰ, collagen Ⅲ, fibronectin, and MMP-9 were clearly suppressed by SFI or nicorandil when compared with the MI/R group ( p2aR and collagen I and collagen III was found ( p = 0.00). Conclusion: SFI activated the A2aR to reduce myocardial fibrosis caused by MI/R injury, which provided an underlying mechanism of action of SFI.
- 31 August 2021
- Published by SAGE Publications in Human & Experimental Toxicology
- Vol. 40 (12_suppl) , S300-S309
Effects of Shenfu injection on myocardial adenosine receptors in rats with myocardial ischemia-reperfusion postconditioning
Objective: Shenfu injection (SFI) has been reported to have a protection against myocardial ischemia-reperfusion (MI/R) injury. However, the changes of adenosine receptors in MI/R postconditioning when pretreated with SFI are unclear. Methods: Forty-five rats were randomly divided into sham group (sham), MI/R postconditioning group (MI/R-post), low-dose SFI group (1 mL/kg), middle-dose SFI group (2.5 mL/kg), and high-dose SFI group (5 mL/kg). In SFI groups, SFI was intravenously injected before reperfusion, and rats were treated with ischemic postconditioning after ischemia for 30 min. After 24 h of reperfusion, the levels of Ca2+ and cAMP in blood platelets were analyzed. Myocardial infarct volume and myocardial pathology were observed. The levels of adenosine receptor subtypes A1, A2b, and A3 in myocardium were analyzed using immunohistochemistry and Western blot. The oxidative stress–related indicators were also observed. Results: Compared with the MI/R-post group, SFI ameliorated the MI/R injury by decreasing the myocardial infarct area, oxidative stress, and concentration of Ca2+ and cAMP ( p < 0.01). Pretreatment with SFI enhanced the expression of adenosine receptors A1 and A2b in a dose manner compared with the MI/R-post group. In contrast, the levels of adenosine receptor A3 were increased after MI/R postconditioning compared with the sham group, and its expression continued to increase with the increase of SFI. Furthermore, the oxidative stress reduced with the concentrations of SFI. Conclusion: These results demonstrated that pretreatment with SFI might regulate the expression of adenosine receptors to improve the MI/R postconditioning.
- 31 August 2021
- Published by SAGE Publications in Human & Experimental Toxicology
- Vol. 40 (12_suppl) , S300-S309
Effects of Shenfu injection on myocardial adenosine receptors in rats with myocardial ischemia-reperfusion postconditioning
Objective: Shenfu injection (SFI) has been reported to have a protection against myocardial ischemia-reperfusion (MI/R) injury. However, the changes of adenosine receptors in MI/R postconditioning when pretreated with SFI are unclear. Methods: Forty-five rats were randomly divided into sham group (sham), MI/R postconditioning group (MI/R-post), low-dose SFI group (1 mL/kg), middle-dose SFI group (2.5 mL/kg), and high-dose SFI group (5 mL/kg). In SFI groups, SFI was intravenously injected before reperfusion, and rats were treated with ischemic postconditioning after ischemia for 30 min. After 24 h of reperfusion, the levels of Ca2+ and cAMP in blood platelets were analyzed. Myocardial infarct volume and myocardial pathology were observed. The levels of adenosine receptor subtypes A1, A2b, and A3 in myocardium were analyzed using immunohistochemistry and Western blot. The oxidative stress–related indicators were also observed. Results: Compared with the MI/R-post group, SFI ameliorated the MI/R injury by decreasing the myocardial infarct area, oxidative stress, and concentration of Ca2+ and cAMP ( p < 0.01). Pretreatment with SFI enhanced the expression of adenosine receptors A1 and A2b in a dose manner compared with the MI/R-post group. In contrast, the levels of adenosine receptor A3 were increased after MI/R postconditioning compared with the sham group, and its expression continued to increase with the increase of SFI. Furthermore, the oxidative stress reduced with the concentrations of SFI. Conclusion: These results demonstrated that pretreatment with SFI might regulate the expression of adenosine receptors to improve the MI/R postconditioning.
- 1 November 2009
- Published by Wolters Kluwer Health in Coronary Artery Disease
- Vol. 20 (7) , 467-472
Prognostic role of brachial reactivity in patients with ST myocardial infarction after percutaneous coronary intervention
Objective We hypothesized that flow-mediated vasodilation (FMD) in the brachial artery as a noninvasive method is of value in providing further predictive insights in a cohort of patients with ST-segment elevation acute myocardial infarction (STEMI) after percutaneous coronary intervention (PCI). Methods and results One hundred and one patients (62.43±9.06, 67 men) with STEMI, undergoing successful primary and rescue PCI, were included in this study. FMDs of all patients were determined using ultrasound after PCI. Patients were tracked for subsequent cardiovascular events. Twenty-nine patients had an event during 12.1±2.6 months of follow-up. Multivariate Cox proportional hazard analysis identified a diagnosis of diabetes [hazard ratio (HR): 2.934, 95% confidence interval (CI): 1.314−6.548, P=0.0086], ejection fraction (HR: 0.900, 95% CI: 0.832−0.973, P=0.0082), and FMD (HR: 0.705, 95% CI: 0.573−0.868, P=0.0010) after adjustment of all entered baseline variables. ROC analysis showed that FMD (ROC area: 0.689, P=0.0012; optimal threshold: 5.5% or less) had predictive value with sensitivity of 64%, specificity of 61%, positive predictive value of 40%, and negative predictive value of 81%. Conclusion In patients with STEMI, early evaluation of endothelial function after PCI could help to shed light on the mechanisms that increase the risk of new events. FMD could be used as a surrogate marker of events.
- 1 November 2009
- Published by Wolters Kluwer Health in Coronary Artery Disease
- Vol. 20 (7) , 467-472
Prognostic role of brachial reactivity in patients with ST myocardial infarction after percutaneous coronary intervention
Objective We hypothesized that flow-mediated vasodilation (FMD) in the brachial artery as a noninvasive method is of value in providing further predictive insights in a cohort of patients with ST-segment elevation acute myocardial infarction (STEMI) after percutaneous coronary intervention (PCI). Methods and results One hundred and one patients (62.43±9.06, 67 men) with STEMI, undergoing successful primary and rescue PCI, were included in this study. FMDs of all patients were determined using ultrasound after PCI. Patients were tracked for subsequent cardiovascular events. Twenty-nine patients had an event during 12.1±2.6 months of follow-up. Multivariate Cox proportional hazard analysis identified a diagnosis of diabetes [hazard ratio (HR): 2.934, 95% confidence interval (CI): 1.314−6.548, P=0.0086], ejection fraction (HR: 0.900, 95% CI: 0.832−0.973, P=0.0082), and FMD (HR: 0.705, 95% CI: 0.573−0.868, P=0.0010) after adjustment of all entered baseline variables. ROC analysis showed that FMD (ROC area: 0.689, P=0.0012; optimal threshold: 5.5% or less) had predictive value with sensitivity of 64%, specificity of 61%, positive predictive value of 40%, and negative predictive value of 81%. Conclusion In patients with STEMI, early evaluation of endothelial function after PCI could help to shed light on the mechanisms that increase the risk of new events. FMD could be used as a surrogate marker of events.